On the fly News and insights, exclusive to thefly.com

MRK

Merck

$82.32 /

-0.48 (-0.58%)

, PFE

Pfizer

$50.90 /

-0.195 (-0.38%)

09:18
11/26/21
11/26
09:18
11/26/21
09:18

Merck drops 4% after Covid pill efficacy drops in larger dataset

Shares of Merck (MRK) are falling after the company provided an update on molnupiravir, its investigational oral antiviral medicine for Covid-19. Data are now available from all of the enrolled 1433 participants. In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group to 6.8% in the molnupiravir group, for an absolute risk reduction of 3.0% and a relative risk reduction of 30%. Nine deaths were reported in the placebo group, and one in the molnupiravir group. The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis, Merck and partner Ridgeback Biotherapeutics said in a statement. The relative risk reduction of 30% is down from the 48% the companies reported previously for molnupiravir. Shares of Merck are down 4% to $78.73 in premarket trading following the data while Pfizer, which is also developing a Covid antiviral treatment, is up 6% to $54.10.

MRK

Merck

$82.32 /

-0.48 (-0.58%)

PFE

Pfizer

$50.90 /

-0.195 (-0.38%)

  • 28

    Nov

  • 30

    Nov

  • 03

    Dec

  • 04

    Dec

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 10

    Dec

  • 21

    Dec

  • 29

    Dec

  • 23

    Jan

  • 24

    Jan

  • 03

    Feb

  • 21

    Mar

  • 28

    Mar

  • 06

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.